Core Viewpoint - The company, Xiangyu Medical, has noted increased market attention on brain engineering and brain-machine interface concepts, leading to significant stock price increases in related sectors [1] Company Focus - The company primarily focuses on non-invasive brain-machine interface technology, which encompasses a comprehensive rehabilitation layout including occupational therapy, motor therapy, cognitive speech, and swallowing [1] - This approach differs from the current international trend towards invasive brain-machine interface technologies [1] Market Position and Development - The company has made investments in brain-machine interface technology, establishing a certain level of layout in technology, products, and market channels [1] - However, the company faces delays in bidding and sales processes, with related products not expected to achieve large-scale sales until the end of 2025, resulting in a small revenue contribution [1]

Core Viewpoint - The stock of Xiangyu Medical has experienced significant volatility, with a cumulative price deviation of 30% over three consecutive trading days, attributed to heightened market interest in brain engineering and brain-computer interface concepts [1] Company Focus - The company is primarily focused on non-invasive brain-computer interface technology, which encompasses a comprehensive range of rehabilitation scenarios including occupational therapy, motor therapy, cognitive speech, and swallowing [1] - This approach differs from the current international trend towards invasive brain-computer interface technologies [1] Market Position and Development - The company has made investments in brain-computer interface technology, establishing a certain level of layout in technology, products, and market channels [1] - However, the bidding and sales processes exhibit a lag, and as of the end of 2025, related products are not expected to achieve large-scale sales, resulting in a relatively small revenue contribution [1]

Core Viewpoint - The stock of Xiangyu Medical has experienced unusual fluctuations due to increased market attention on brain engineering and brain-computer interface concepts, leading to significant price increases in related sectors [1] Company Focus - The company primarily focuses on non-invasive brain-computer interface technology, covering a comprehensive range of rehabilitation scenarios including occupational therapy, motor therapy, cognitive speech, and swallowing [1] - This approach differs from the current international trend towards invasive brain-computer interface technologies [1] Market Position and Development - The company has made certain advancements in technology, products, and market channels related to brain-computer interfaces [1] - However, the bidding and sales processes exhibit a lag, and as of the end of 2025, related products are not expected to achieve large-scale sales, resulting in a small revenue contribution [1]

Core Viewpoint - The company announced abnormal stock price fluctuations, with a cumulative deviation of 30% in closing prices on specific dates in late 2025, indicating potential volatility in the stock market [1] Financial Performance - For the first three quarters of 2025, the company reported revenue of 537.03 million yuan, representing a year-on-year increase of 6% [1] - The net profit for the same period was 43.98 million yuan, showing a significant year-on-year decline of 40.09% [1] Business Focus - The company is concentrating on non-invasive brain-machine interface technology, although related products had not achieved large-scale sales by the end of 2025, resulting in a small revenue contribution [1]